About Bcl-2/adenovirus E1B 19 kDa-interacting protein 2-like protein
Bcl-2/adenovirus E1B 19 kDa-interacting protein 2-like protein (BNIPL) is a protein
from Homo sapiens identified by UniProt accession
Q7Z465, 357 residues long.
MolForge cross-references it against 0 known binders and
43 disease associations.
Target properties
| Protein name | Bcl-2/adenovirus E1B 19 kDa-interacting protein 2-like protein |
| UniProt accession | Q7Z465 |
| Gene | BNIPL |
| Organism | Homo sapiens |
| Length | 357 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (43)
Diseases linked to this target (Open Targets).
- body mass index · score 0.15
- calcium measurement · score 0.14
- osteoporosis · score 0.11
- age at first sexual intercourse measurement · score 0.08
- BMI-adjusted waist-hip ratio · score 0.06
- non-melanoma skin carcinoma · score 0.04
- skin cancer · score 0.04
- age at menarche · score 0.04
- esophageal adenocarcinoma · score 0.04
- appendicular lean mass · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q7Z465-F1 | alphafold | PREDICTED | 67.44 | — |
Amino-acid sequence (357 residues)
MGTIQEAGKK TDVGVREIAE APELGAALRH GELELKEEWQ DEEFPRLLPE EAGTSEDPED PKGDSQAAAG TPSTLALCGQ RPMRKRLSAP ELRLSLTKGP GNDGASPTQS APSSPDGSSD LEIDELETPS DSEQLDSGHE FEWEDELPRA EGLGTSETAE RLGRGCMWDV TGEDGHHWRV FRMGPREQRV DMTVIEPYKK VLSHGGYHGD GLNAVILFAS CYLPRSSIPN YTYVMEHLFR YMVGTLELLV AENYLLVHLS GGTSRAQVPP LSWIRQCYRT LDRRLRKNLR ALVVVHATWY VKAFLALLRP FISSKFTRKI RFLDSLGELA QLISLDQVHI PEAVRQLDRD LHGSGGT
Explore Bcl-2/adenovirus E1B 19 kDa-interacting protein 2-like protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets